WHO’s New Pricing Policy Guideline Makes Medicines More Affordable
October 12, 2020
A new WHO guideline aims to help governments overcome the barrier of high prices for pharma products, enabling them to better address public health needs. Over 50 international experts from a diverse array of stakeholder groups evaluated and assessed scientific evidence and country experiences to prepare the guideline covering THE FOLLOWING 10 policy pricing approaches:
- External reference pricing
- Internal reference pricing
- Value-based pricing
- Regulation of mark-ups across the pharmaceutical supply and distribution chain
- Promoting price transparency
- Tendering and negotiation
- Promoting the use of quality assured generic and biosimilar medicines
- Pooled procurement
- Cost-plus pricing
- Tax exemptions or tax reductions
Read more here.